Swedish medical technology group Getinge reported third-quarter profit that beat analyst expectations, saying price increases and a more favorable product mix helped offset the impact of US tariffs. The company, which makes equipment for operating rooms, intensive care units, and sterilization, said adjusted EBITA—operating profit before certain one-off items—rose 18% to 1.28 billion Swedish crowns in the quarter. That came in above the 1.19 billion crowns that analysts had forecast in a company poll cited by Reuters.
What's behind the beat?
Getinge's management credited a combination of factors for the stronger-than-expected result. Along with pricing moves and a better mix of higher-margin products, the company said it benefited from tariff refunds and favorable currency effects. It also pointed to ongoing cost-reduction efforts and supply-chain adjustments that helped cushion the blow from US import duties.
The company noted that more than 60% of its products are manufactured in the US, which can limit its exposure to import tariffs. That domestic production base means a significant portion of its goods sold in the US are not subject to the same levies as imported rivals, giving Getinge a degree of insulation from trade friction.
Getinge's performance comes as many European manufacturers grapple with the ripple effects of US trade policy. Tariffs on imported goods have squeezed margins across industries, forcing companies to either absorb higher costs or pass them on to customers. Getinge's ability to lean on pricing and product mix suggests it has some pricing power in its markets, a trait that investors often value in uncertain times.
What it means for investors
For everyday investors, the key takeaway is that Getinge managed to grow profits at a solid clip even in a challenging trade environment. The beat shows that the company's strategy of focusing on higher-value products and operational efficiency is paying off, at least for now.
However, it's worth noting that the profit figure was helped by one-off items like tariff refunds and currency swings. Those are not necessarily repeatable, so investors should look beyond the headline number to assess the underlying health of the business. The company's ability to sustain pricing and mix improvements will be crucial in the coming quarters, especially if tariff policies shift again.
Getinge's results also offer a glimpse into the broader European earnings season. As analysts lift profit forecasts across the region, companies that can navigate cost pressures and trade disruptions are likely to stand out. Getinge's beat is a positive signal, but it also highlights the uneven impact of tariffs across sectors.
For those watching the medical technology space, Getinge's performance contrasts with other recent earnings reports. For instance, DNB beat profit forecasts in banking, while SKF beat forecasts but warned about demand volatility. These mixed signals suggest that while some companies are managing well, the broader economic environment remains uncertain.
Looking ahead
Investors will be watching whether Getinge can maintain its momentum. The company's reliance on US production is a double-edged sword: it shields it from import tariffs, but it also means any slowdown in US healthcare spending could hit demand. Additionally, currency movements can be unpredictable, and the benefit from tariff refunds may not recur.
Getinge's focus on pricing and product mix is a common strategy among medtech firms facing cost pressures. As some analysts have flagged margin squeezes from product mix in other sectors, Getinge's ability to turn mix into a tailwind is notable.
For now, the market reaction to Getinge's numbers will likely be positive, given the clear beat. But as always, investors should consider the sustainability of these gains and the risks that lie ahead, including potential changes in trade policy and healthcare demand.
